VIDEO: New therapeutics improve multiple myeloma outcomes

Editor’s note: This is a previously posted video, and the below is an automatically generated transcript to be used for informational purposes. Please notify editor@healio.com if there are concerns regarding accuracy of the transcription.

The standard of care for multiple myeloma has evolved so dramatically. So, I started out in the bad old days, not at City of Hope, but in my prior fellowship training where median survival for multiple myeloma was roughly 18 months. And we essentially had three regimens. We had melphalan and prednisone, a regimen called VAD, and then we had an agglomeration of all those things called M2. Not a very effective or deep portfolio, and what we've seen is that as we've added in new therapeutics from multiple classes, that options and outcomes for patients have dramatically improved. So, median survival, again, starting out in 1990 as a resident and subsequently fellow at Stanford, median survival was like 18 months. Currently at City of Hope, median survival exceeds 10 years. And I have patients in my clinic for whom I have been caring for them, for multiple myeloma, for extraordinarily advanced stage, aggressive disease for 14 plus years. So, these new therapeutics have translated into a profound life dividend for patients. CAR T-cells add to that mix. I think the value-add and the potential impact of these immuno oncological, targetable living therapeutics adds something decidedly new. What this does to alter the, you know, the survival curve for myeloma is something that we'll be following very, very closely. But I think this is a profoundly exciting add to the therapies that we have available in our portfolio for patients and families that is really changing what we think about myeloma.